Efficacy of rivaroxaban for pulmonary embolism
Juan Jia, MB³, Shi-min Xue, MM⁴, Ning Xu, MM³,*

Abstract

Background: Previous clinical trials have addressed that rivaroxaban is effective for the treatment of patients with pulmonary embolism (PE). This study will systematically assess its efficacy and safety for PE.

Methods: We will carry out this study by searching the following electronic databases from inception to March 1, 2019 without language restrictions: Cochrane Library, EMBASE, PUBMED, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. In addition, we will also search clinical trial registries, dissertations, and conference abstracts to avoid any missing potential studies. All randomized controlled trials of rivaroxaban for patients with PE will be fully considered. Two researchers will independently perform literature selection, data collection, and methodological quality assessment. If it is appropriate, outcome data will be pooled by using a fixed-effect model or random-effect model, and meta-analysis will be considered for operation.

Results: All efficacy and safety of rivaroxaban for PE will be assessed through all primary and secondary outcomes. The primary outcomes are all-cause mortality and major bleeding. The secondary outcomes are recurrent venous thromboembolism, duration of hospital stay, quality of life, patient satisfaction, and adverse events.

Conclusion: The findings of this study will summarize updated evidence on the efficacy and safety of rivaroxaban for patients with PE.

Ethics and dissemination: It is not necessary to inquire ethical approval for this study, because it will not analyze any individual patient data. The results of this study will be published through peer-reviewed journals.

Systematic review registration: PROSPERO CRD42019126095.

Abbreviations: PE = pulmonary embolism, TSQM-II = Treatment Satisfaction Questionnaire for Medication version II, VTE = venous thromboembolism.

Keywords: efficacy, pulmonary embolism, rivaroxaban, systematic review

1. Introduction

Venous thromboembolism (VTE), which consists of deep vein thrombosis and pulmonary embolism (PE), is a very tricky condition at clinic.1–4 It is often associated with very high mortality and morbidity in patients with such condition.1,4 It has been reported that about 20% of patients with VTE died before or one day after they diagnosed with VTE. Furthermore, about 11% of the VTE survivors still may die due to the variety of complications within 3 months.5,6 Of such condition, PE is a potential life-threatening disease, especially acute PE that requires urgent intervention. It is also the third leading reason of death in patients with cardiovascular diseases, following coronary heart attack, and stroke.7 It has been estimated that the incidence of PE is about 69 per 100,000 every year. Most importantly, its associated mortality risk is reported to more than 20% and 65% of deaths happening within 1 hour.8–10 Furthermore, such mortality risk may still persist with 5%, and lasts up to 12 months.11

Standard therapy for PE comprises of warfarin, a dose-adjusted vitamin K antagonist.12–14 It is an oral anticoagulant for the treatment of PE. However, its anticoagulation effect cannot work as immediate-acting parenteral agent until after 4–5 days treatment.15–17 Additionally, it also requires strict dietary, and regular monitor for anticoagulation effect to keep international normalized rate (INR) within the range of 2.0–3.0.18

Rivaroxaban is a specific developed oral anticoagulant with rapid onset of action.19 It is also a direct Factor Xa inhibitor, which does not need for routine INR monitoring.19,20 A numerous clinical trials have reported that rivaroxaban is effective for patients with PE.21,22 Furthermore, although a systematic review has addressed to assess the benefits of rivaroxaban for PE involving observational studies only, and search date up to November 2016,23 lots of high quality randomized controlled trials (RCTs) were published after that study.24–38 Thus, this updated study will systematically evaluate the efficacy and safety of rivaroxaban for PE, and will provide its latest updated evidence.

2. Methods

2.1. Study registration

This study has been registered on PROSPERO (CRD42019126095). The systematic review protocol will be
Table 1
Search strategy used in Cochrane Library database.

| Number | Search terms |
|--------|--------------|
| 1 | Mesh descriptor: (pulmonary embolism) explode all trees |
| 2 | Mesh descriptor: (venous thrombosis) explode all trees |
| 3 | (pulmonary*) OR [embolism*] OR [thrombo-embolism*] OR [infarct*] OR [venous or deep vein*] OR [thrombosis*] OR [thromboembolism*]:ti, ab, kw |
| 4 | Or 1–3 |
| 5 | Mesh descriptor: (rivaroxaban) explode all trees |
| 6 | (rivaroxaban*) OR [xarelto*] OR [anticoagulant medication*] OR [blood thinner *]:ti, ab, kw |
| 7 | Or 5–6 |
| 8 | MeSH descriptor: (randomized controlled trials) explode all trees |
| 9 | (random *) OR [allocation *] OR [placebo *] OR [sham *] OR [blind *] OR [control trial *] OR [RCT *] OR [clinical trials *]:ti, ab, kw |
| 10 | Or 8–9 |
| 11 | 4 and 7 and 10 |

reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.[139]

2.2.2.4. Type of outcome measurements
2.2.4.1. Primary outcomes. All-cause mortality; Major bleeding (as assessed by simplified Pulmonary Embolism Severity Index score, or other instruments).
2.2.4.2. Secondary outcomes. Recurrent venous thromboembolism; Duration of hospital stay; Quality of life (as evaluated by Global Quality of Life Scale or other tools); Patient satisfaction (as measured by generic Treatment Satisfaction Questionnaire for Medication version II or other scales); Adverse events (any expected and unexpected adverse events).

2.4. Study selection
Two researchers will perform all study selection independently. Any conflict regarding the study selection between two researchers will be solved by a third researcher through discussion. At the first stage, they will review the titles and abstracts of all records to identify any potential studies based on the predefined eligibility criteria. At the second stage, full-texts of all potential relevant studies will be read for further judgments. The whole study selection procedure will abide to the PRISMA guidelines, and will be showed in PRISMA flowchart.

2.5. Data extraction and management
A standard data extraction form will be created before the data collection. Two researchers will independently collect all the important information and extract data from each eligible study. Any conflicts between two researchers will be settled down by a third researcher. The extracted information includes: general characteristics of eligible studies (e.g., first author name, published year, country, sample size, eligibility criteria, and so on), details of patients (e.g., sex, age, and so on), details of treatments (e.g., drug, dosage, frequency, route, and so on), and outcomes (e.g., primary, secondary, and other outcome measurements).

2.6. Missing data
Any missing data will be required by contacting primary authors with emails. If we cannot receive those data, we will only analyze available data, and will discuss it.

2.7. Methodological quality assessment
Cochrane risk of bias tool will be used to evaluate the methodological quality for each eligible trial. It will be divided into 7 aspects, and each aspect will be classified as low risk, unclear, or high risk. Two independent researchers will perform the whole process of methodological quality assessment. If there are disagreements, a third researcher will help to resolved them by discussion.
2.8. Strategy for data synthesis

2.8.1. Measurement of treatment effect. As for dichotomous values, we will record them as risk ratio with 95% confidence intervals (CIs). As for continuous values, we will record them as mean difference or standardized mean difference with 95% CIs. If $I^2$ is less than 50%, low heterogeneity is regarded. Then, we will use a fixed-effect model to synthesize the data. Meanwhile, meta-analysis will be carried out by using RevMan version 5.3 software. If $I^2$ is more than 50%, high heterogeneity is considered, and subgroup analysis will be conducted. If there is low heterogeneity after subgroup analysis, we will pool the data by using a random-effect model, and we will also carry out meta-analysis. If there is still high heterogeneity after subgroup analysis, we will not synthesize the data, and only a narrative summary will be reported.

2.8.2. Data synthesis. We will judge heterogeneity by using $I^2$ test. If $I^2$ is less than 50%, low heterogeneity is regarded. Then, we will use a fixed-effect model to synthesize the data. Meanwhile, meta-analysis will be carried out by using RevMan version 5.3 software. If $I^2$ is more than 50%, high heterogeneity is considered, and subgroup analysis will be conducted. If there is low heterogeneity after subgroup analysis, we will pool the data by using a random-effect model, and we will also carry out meta-analysis. If there is still high heterogeneity after subgroup analysis, we will not synthesize the data, and only a narrative summary will be reported.

2.8.3. Subgroup analysis. Subgroup analysis will be carried out based on the different treatments, controls, and outcomes.

2.8.4. Sensitivity analysis. Sensitivity analysis will also be performed to check the robustness of pooled results by eliminating the impact of low-quality studies.

2.8.5. Reporting bias. The funnel plot and Egger’s test will be performed to evaluate the reporting bias if at least 10 trials are included.

3. Discussion

Although a previous relevant study has been published in 2017, it only included observational studies up to the November 2016 with quite low level of evidence, and lots of high-quality RCTs have been published after that study. This updated study protocol will only include higher level evidence of RCTs, and will systematically assess the efficacy and safety of rivaroxaban for patients with PE. Its results will summarize the latest updated evidence on assessing the efficacy and safety of rivaroxaban for PE. It may also present solid data and robust evidence either to the clinical practice, and future studies, or to the health policy makers.

Author contributions

Conceptualization: Juan Jia, Ning Xu. Data curation: Juan Jia, Shi-min Xue, Ning Xu. Formal analysis: Juan Jia, Shi-min Xue. Funding acquisition: Ning Xu. Investigation: Ning Xu. Methodology: Juan Jia, Shi-min Xue. Project administration: Ning Xu. Resources: Juan Jia, Shi-min Xue. Software: Shi-min Xue. Supervision: Ning Xu. Validation: Juan Jia, Shi-min Xue, Ning Xu. Visualization: Juan Jia, Shi-min Xue, Ning Xu. Writing – original draft: Juan Jia, Shi-min Xue, Ning Xu. Writing – review & editing: Juan Jia, Shi-min Xue, Ning Xu.

References

[1] Coon WW. Venous thromboembolism. Prevalence, risk factors, and prevention. Clin Chest Med 1984;5:391-401.

[2] Bartholomew JR. Update on the management of venous thromboembolism. Cleve Clin J Med 2017;84(Suppl 3):39–46.

[3] Zhang Z, Tang L, Hu Y. Progress in the research on venous thromboembolism. J Huazhong Univ Sci Technol Med Sci 2017;37: 811–5.

[4] Winters MP, Scherthanhaer GH, Lang IM. Chronic complications of venous thromboembolism. J Thromb Haemost 2017;15:1531–40.

[5] White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:34–8.

[6] Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013;126:832e813–821.

[7] Goldhaber SZ, Pourmalek F. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835–46.

[8] Silverstein MD, Hade J, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585–93.

[9] Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1999;108: 793–800.

[10] Anderson FAJr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933–8.

[11] Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:122–30.

[12] Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 2004;126:2045S–33S.

[13] Aujesky D, Rooy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378: 41–8.

[14] Zondag W, Mos ICM, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9:1500–7.

[15] Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472–7.

[16] White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167: 239–46.

[17] Prins MH, Bamber I, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015;135:281–8.

[18] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S–965.

[19] Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010;30:376–81.

[20] Sarich TC, Peters G, Berkowitz SD, et al. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann NY Acad Sci 2013;1291:42–55.

[21] The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–510.

[22] The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–97.

[23] Kohn CG, Ferrmann GJ, Peacock WF, et al. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world cases. Curr Med Res Opin 2017;33:1697–703.

[24] Groetzinger LM, Miller TJ, Rivosecchi RM, et al. Apixaban or rivaroxaban versus warfarin for treatment of submassive pulmonary embolism after catheter-directed thrombolysis. Clin Appl Thromb Hemost 2018;24:908–13.

[25] Shen ZF. Clinical efficacy and safety of rivaroxaban in the treatment of acute pulmonary embolism. Chin Community Physician 2018;34: 47–8.

[26] Cai XY, Sun J. Clinical observation of rivaroxaban in the treatment of middle-risk pulmonary embolism. World Med Inf Dis 2018;18: 101–4.
[27] Liang S. Therapeutic effect of comprehensive nursing intervention combined with rivaroxaban in patients with acute pulmonary thromboembolism combined with deep venous thrombosis of lower extremity. Heilongjiang Med 2018;42:1025–6.

[28] Liang LD, Lin MK, Zhou W, et al. The effect of rivaroxaban combined with low-division heparin calcium in the treatment of advanced lung cancer with pulmonary embolism. Chin J Gerontol 2018;38:4385–7.

[29] Sun GL, Qiao W, Gao SJ. Clinical effect of rivaroxaban in the treatment of pulmonary embolism. Chin Prescr Drugs 2018;16:66–7.

[30] Ye GS. Effect of rivaroxaban on pulmonary embolization anticoagulant therapy, incidence of adverse reactions and effects on vascular endothelial function in patients. Chin Pract Med 2018;13:93–4.

[31] Wei XL, Guli KD. Observing the clinical efficacy of rivaroxaban in the treatment of patients with pulmonary embolism. Chin Foreign Med Treat 2018;37:105–6.

[32] Huang H, Huang XD, Lin CQ. Therapeutic effect of rivaroxaban on acute pulmonary embolism. China Mod Pharm Appl 2018;12:88–90.

[33] Tian H, Wang H, Wang YP, et al. Clinical observation of rivaroxaban in the treatment of venous thromboembolism. Chin Foreign Med Res 2018;16:45–7.

[34] Tang KW, Mo GQ, Pan YC. Clinical efficacy of low molecular weight heparin combined with rivaroxaban in the treatment of acute pulmonary embolism. J Clin Ration Drug Use 2018;11:55–6.

[35] Ren JF, Si QJ. Study on the efficacy and safety of different regimens of rivaroxaban in the prevention and treatment of elderly patients with thromboembolic diseases. Chin J Geriatr Cardiovasc Cerebrovasc Dis 2018;20:367–70.

[36] Jiang G, Zhang WD, Peng ML. Clinical significance of rivaroxaban in the treatment of acute intermediate-risk pulmonary thromboembolism combined with deep venous thrombosis of lower extremity. Chin J Respir Crit Care 2018;17:172–7.

[37] Wu X, Cui WN, Wang SM, et al. Effects of rivaroxaban on D-dimer level and quality of life in patients with acute pulmonary embolism. Chin Lab Diagn 2018;22:230–3.

[38] Huang XG, Wang LY, Chen XL. Therapeutic effect of rivaroxaban on acute pulmonary embolism after stroke. Chin J Pract Nerv Dis 2017;20:32–5.

[39] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.